Changes in the chairman of two well-known pharmaceutical companies

Position changes of 21 medical personnel, involving 2 chairman of pharmaceutical companies

01 The chairman of a well-known pharmaceutical company resigned

01 The chairman of a well-known pharmaceutical company resigned

Just over half of November, many senior executives of pharmaceutical companies have resigned.
Among them, the chairman of two pharmaceutical companies has changed, namely First Pharmaceutical and Ruizhi Pharmaceutical (see the end of the article for details)
.

On November 12, Shanghai First Pharmaceutical issued an announcement stating that Xu Ziying had resigned as chairman, director, chairman of the Strategic Committee of the Board of Directors, and member of the Remuneration and Appraisal Committee due to work reasons, and would no longer hold any position in First Pharmaceutical after resignation
.

It is understood that First Pharmaceutical’s main business is pharmaceutical retail and pharmaceutical wholesale, accounting for 61.
77% and 34.
25% of revenue respectively
.

The report for the third quarter of 2021 shows that during the reporting period, First Pharmaceutical’s main operating income was 365 million yuan, an increase of 8.
34% year-on-year; the net profit attributable to the parent was 10.
015 million yuan, a year-on-year decrease of 58.
97%; non-net profit was 1,597,500 yuan, a year-on-year decrease of 80.
5 %; debt ratio is 40.
14%
.

As for the reasons for the decline in performance, it explained in the semi-annual report that it was mainly affected by the demand for civilian anti-epidemic materials and the decline in prices
.

In addition, under the influence of national policies, the pharmaceutical distribution industry has become more competitive in the industry, leading companies have obvious advantages, and the rise of new business forms such as Internet hospitals is also an important factor affecting its development

On October 28, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period", which clearly put forward the requirements for increasing industry concentration
.

According to the above requirements, the structure of the pharmaceutical distribution industry will be further optimized, leading companies will gain more market share, and continuous mergers and acquisitions will become the main theme of the pharmaceutical business in the next few years

In fact, this transformation is already underway gradually
.

In recent years, the pharmaceutical industry in the upstream of the pharmaceutical distribution industry has begun market restructuring under the influence of policies such as "volume procurement".
At the same time, the market of pharmaceutical wholesale companies is also being re-segmented, and the competitive advantages of leading companies have become more apparent
.

For example, the four major pharmacies all stated in their financial reports that under the background of the normalization of volume procurement, they will actively undertake the centralized procurement business.
In addition, strengthening the construction of DTP pharmacies is also an unanimous choice
.

With the deepening of medical reform, its impact on the industry is all-round from top to bottom
.

For pharmaceutical companies, it is necessary to recognize changes in the industry in time

In addition, the development of online medical care will also divert offline pharmacies to a certain extent
.

With the rise of Internet hospitals, the pilot of online medical insurance payment, the conditional liberalization of online prescription drugs, and the liberalization of pharmacy spacing restrictions, policies will intensify the competition for passenger flow both online and offline

Facing the complex market environment and fierce industry competition, enterprises must have a clear development direction on the one hand, and learn to innovate in accordance with local conditions on the other
.

According to the third-quarter financial report of First Pharmaceuticals, there were 110 stores at the end of the previous period.
During the reporting period, 4 new stores were opened and 2 were relocated.
In addition, it is continuing to implement transformation measures such as online and offline integration to explore "Internet + medical health".
New business models in other fields
.

To a certain extent, the senior executives play a role in formulating the company's development strategy and clarifying the future development direction.
With the change of the chairman, whether the future performance of First Pharmaceutical will change is expected
.

On the evening of November 1, Ruizhi Medicine issued an announcement stating that the board of directors had recently received a written resignation report from the chairman WOO SWEE LIAN.
WOO SWEE LIAN applied for resignation as chairman, director, and chairman of the strategy committee of the board due to personal reasons, and continued after resignation Acting as a strategic consultant
.

In addition to First Pharmaceutical and Ruizhi Pharmaceutical, it can be seen that in November, another vice chairman resigned and one vice chairman took office
.

02 Frequent changes in executives

02 Frequent changes in executives

It is not surprising that policy-driven changes in the industry and frequent changes in company executives are not surprising
.

On November 1, Lai Minglong, general manager of AstraZeneca China announced a personnel change to employees.
Du Haochen, vice president of AstraZeneca China and head of the county business department, decided to leave the company due to personal reasons.
The last working day is the 17th of this month.
Day
.

It is worth noting that Du Haochen is AstraZeneca's fifth executive resignation after Dong Lijun, Xu Jing, Zhang Anwei, and He Yimin since July this year

It is understood that Du Haochen left Pfizer in 2015 to join AstraZeneca, as the national head of the county business department, and organized and led AstraZeneca and county teams to implement the "expansion and sink" strategy
.

"Expanding and sinking" is one of AstraZeneca’s three basic strategies.
In recent years, under the policy background of hierarchical diagnosis and treatment, mass procurement, prescription outflow, etc.
, in addition to AstraZeneca, Bayer, Pfizer, Sanofi, Many multinational pharmaceutical companies such as Novo Nordisk have a presence in the primary medical market
.

For example, in 2019, Pfizer added 1,000 medical representatives to the county-level market, while AstraZeneca deployed sales staff in more than 500 counties across the country to form AstraZeneca’s county-level marketing team
.

The result of the expansion of the layout is the gradual increase in the number of grassroots sales.
Data shows that the growth rate of foreign pharmaceutical companies in second-tier, third-tier, and fourth-tier cities in 2018 was as high as 10.
9%, 11.
9%, and 8.
8%; The growth rates of second-tier, third-tier, and fourth-tier cities are as high as 13.
8%, 15.
5%, and 22.
3% respectively
.

But now, with the regularization of centralized procurement, competition in the county market is gradually expanding.
In addition to competition between multinational companies, there are also competitions with local innovative companies
.

To this end, multinational pharmaceutical companies have continuously reduced the county-level general drug team on the one hand, and on the other hand have begun to deploy the innovative drug market and expand the specialty drug county-level team

In November, another personnel change that attracted the attention of many medical professionals was the resignation of Qian Wei, the chief commercial officer of Junshi Bio
.

On November 3, Junshi Biotech officially announced to employees that the chief commercial officer Qian Wei has recently resigned due to personal development reasons, and the last working day is November 12, 2021
.

It is understood that Qian Wei has previously worked in many multinational pharmaceutical companies such as Eli Lilly, Nutricia, AstraZeneca, Roche, and so on.
He left Roche on June 30 this year and joined Junshi Bio in July, responsible for managing Junshi Bio’s sales.
team, marketing strategy, marketing, medical affairs oncology department, training department and other sales
.

In 2019, Junshi’s PD-1 monoclonal antibody achieved sales of 774 million yuan, and Cinda’s PD-1 monoclonal antibody was 1.
016 billion yuan
.

In 2020, Junshi’s PD-1 will achieve sales of 1 billion yuan, while Cinda’s PD-1 Daboshu will have sales of 2.

In fact, in the past three years, the head of Junshi Bio's sales has experienced Han Jing, Duan Xin, and Qian Wei.
Perhaps it is not easy to prove this job from the side
.

With the help of capital, domestic biotech is developing well.
The first product has been listed or will be listed soon.
It is in the critical commercialization stage.
It is very important to have a suitable commercialization leader, and frequent personnel changes are inevitable
.

Medical talents who have returned to local development from multinational pharmaceutical companies also need time to clarify their future direction